Likun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Likun Liu has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Dongli Ruan
Department of Medical Imaging, The Affiliated Hospital of Guizhou Medical University, Guiyang City, Guizhou Province, China
2 shared publications - Chunyang Wang
Urology Surgery, PLA General Hospital, Beijing, China
1 shared publication - Fang Gu
Department of Medical Imaging, The Affiliated Hospital of Guizhou Medical University, Guiyang City, Guizhou Province, China
1 shared publication - Jinhui Du
Department of Medical Imaging, The Affiliated Hospital of Guizhou Medical University, Guiyang City, Guizhou Province, China
1 shared publication - Liang Zhang
Urology Surgery, Jiujiang University Clinic College/Hospital, Jiujiang, China
1 shared publication - Xin Liao
Department of Medical Imaging The Affiliated Hospital of Guizhou Medical University Guiyang Guizhou China
1 shared publication
Latest Publications
- Open Access
- 14 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
METTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis
Background: Clinical treatment of liver fibrosis remains a significant challenge, necessitating the identification of molecules and factors capable of preventing or slowing its progression to develop more effective therapeutic targets. This study focuses on the pivotal role of the thioredoxin-interacting protein (TXNIP) in the onset of liver fibrosis and the significant contribution of ferroptosis, initiated by autophagy processes, in mitigating liver fibrosis. Despite this, the precise biological functions and mechanisms of TXNIP-mediated autophagy-dependent ferroptosis in the context of liver fibrosis are not fully understood. Methods: To address these gaps, we utilized a combination of bioinformatics analysis, real-time PCR, western blot, and immunohistochemistry to identify markers associated with liver fibrosis and to assess the roles of TXNIP-mediated autophagy-dependent ferroptosis and RNA methylation in the disease’s progression. Two models of liver fibrosis, induced by CCl4 and bile duct ligation, were employed to investigate the regulatory effect of METTL3 on RBX1 mRNA stability and the consequent impact on liver fibrosis. Results: Our findings demonstrate that METTL3 upregulates RBX1 expression by enhancing the stability of RBX1 mRNA. The increased RBX1 functions as an E3 ligase for TXNIP, facilitating TXNIP ubiquitination and reducing its expression, which subsequently initiates cell ferroptosis and aids in the improvement of liver fibrosis. Conclusions: This study underscores the essential role of TXNIP in the progression of liver fibrosis and suggests that a therapeutic strategy targeting TXNIP ubiquitination-mediated autophagy-dependent ferroptosis could offer a novel approach to treating liver fibrosis. The insights gained from this research provide a solid foundation for the development of innovative therapeutic interventions.
- 14 July 2025
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 9 (8)
Open AccessMETTL3 inhibits liver fibrosis via RBX1 stability and TXNIP-mediated ferroptosis
Background: Clinical treatment of liver fibrosis remains a significant challenge, necessitating the identification of molecules and factors capable of preventing or slowing its progression to develop more effective therapeutic targets. This study focuses on the pivotal role of the thioredoxin-interacting protein (TXNIP) in the onset of liver fibrosis and the significant contribution of ferroptosis, initiated by autophagy processes, in mitigating liver fibrosis. Despite this, the precise biological functions and mechanisms of TXNIP-mediated autophagy-dependent ferroptosis in the context of liver fibrosis are not fully understood. Methods: To address these gaps, we utilized a combination of bioinformatics analysis, real-time PCR, western blot, and immunohistochemistry to identify markers associated with liver fibrosis and to assess the roles of TXNIP-mediated autophagy-dependent ferroptosis and RNA methylation in the disease’s progression. Two models of liver fibrosis, induced by CCl4 and bile duct ligation, were employed to investigate the regulatory effect of METTL3 on RBX1 mRNA stability and the consequent impact on liver fibrosis. Results: Our findings demonstrate that METTL3 upregulates RBX1 expression by enhancing the stability of RBX1 mRNA. The increased RBX1 functions as an E3 ligase for TXNIP, facilitating TXNIP ubiquitination and reducing its expression, which subsequently initiates cell ferroptosis and aids in the improvement of liver fibrosis. Conclusions: This study underscores the essential role of TXNIP in the progression of liver fibrosis and suggests that a therapeutic strategy targeting TXNIP ubiquitination-mediated autophagy-dependent ferroptosis could offer a novel approach to treating liver fibrosis. The insights gained from this research provide a solid foundation for the development of innovative therapeutic interventions.
- 29 April 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (1) , 245-260
Hypermethylated ITGA8 Facilitate Bladder Cancer Cell Proliferation and Metastasis
DNA methylation plays a vital role during the development of tumorigenesis. The purpose of this study is to identify candidate DNA methylation drivers during progression of bladder cancer (BLCA). The methylation spectrum in bladder cancer tissues was detected by CHARM analysis, and methylated ITGA8 was selected for further study due to its low expression. Methylation levels in BLCA tissues and cells were detected with methylated-specific PCR (MSP), while mRNA expression and methylation of ITGA8 were detected by qRT-PCR and MSP. After treatment with 5-Aza-dC (DNA methylation inhibitor), the proliferation, migration, and invasion abilities of BLCA cells were determined by MTT, wound healing, and transwell assays, respectively. Flow cytometric analysis was performed to evaluate any variance in the cell cycle. In addition, the effect of demethylated ITGA8 on BLCA tumor growth was verified with an in vivo xenograft tumor model. Based on the methylation profiling of BLCA, ITGA8 was identified to be hypermethylated. ITGA8 methylation levels in BLCA tissues and cells were upregulated, and 5-Aza-dC significantly suppressed ITGA8 methylation levels and increased ITGA8 mRNA expression. Furthermore, after treatment with 5-Aza-dC, the propagation, migration, and invasiveness of the cancer cells were inhibited, and more cancer cells were arrested at the G0/G1 phase. In vivo assays further demonstrated that 5-Aza-dC could impede BLCA tumor growth by repressing methylation levels of ITGA8 and increasing ITGA8 mRNA expression. Hypermethylated ITGA8 facilitated BLCA progression, and 5-Aza-dC treatment inhibited BLCA cell propagation and metastasis by decreasing methylation levels of ITGA8 and inducing cell cycle arrest.
- 29 April 2023
- Published by Springer Nature in Applied Biochemistry and Biotechnology
- Vol. 196 (1) , 245-260
Hypermethylated ITGA8 Facilitate Bladder Cancer Cell Proliferation and Metastasis
DNA methylation plays a vital role during the development of tumorigenesis. The purpose of this study is to identify candidate DNA methylation drivers during progression of bladder cancer (BLCA). The methylation spectrum in bladder cancer tissues was detected by CHARM analysis, and methylated ITGA8 was selected for further study due to its low expression. Methylation levels in BLCA tissues and cells were detected with methylated-specific PCR (MSP), while mRNA expression and methylation of ITGA8 were detected by qRT-PCR and MSP. After treatment with 5-Aza-dC (DNA methylation inhibitor), the proliferation, migration, and invasion abilities of BLCA cells were determined by MTT, wound healing, and transwell assays, respectively. Flow cytometric analysis was performed to evaluate any variance in the cell cycle. In addition, the effect of demethylated ITGA8 on BLCA tumor growth was verified with an in vivo xenograft tumor model. Based on the methylation profiling of BLCA, ITGA8 was identified to be hypermethylated. ITGA8 methylation levels in BLCA tissues and cells were upregulated, and 5-Aza-dC significantly suppressed ITGA8 methylation levels and increased ITGA8 mRNA expression. Furthermore, after treatment with 5-Aza-dC, the propagation, migration, and invasiveness of the cancer cells were inhibited, and more cancer cells were arrested at the G0/G1 phase. In vivo assays further demonstrated that 5-Aza-dC could impede BLCA tumor growth by repressing methylation levels of ITGA8 and increasing ITGA8 mRNA expression. Hypermethylated ITGA8 facilitated BLCA progression, and 5-Aza-dC treatment inhibited BLCA cell propagation and metastasis by decreasing methylation levels of ITGA8 and inducing cell cycle arrest.